Literature DB >> 12758183

The TB epidemic from 1992 to 2002.

Mario C Raviglione1.   

Abstract

In 1992, less than 20 countries were implementing a sound TB control strategy. At the same time, TB was being resurrected as a major public health problem world-wide after two decades of neglect. Awareness of upward trends in the industrialized countries and MDR-TB outbreaks in large cities were driving forces behind the re-emergence of TB in the international health agenda. New evidence, and consequent estimates, suggested that the situation in developing countries, especially in sub-Saharan Africa, was deteriorating rapidly. Similarly, major increases were observed in the former USSR. It was estimated that some 7-8 million new cases and 2-3 million deaths were occurring annually in the world. The global targets of reaching 85% cure rates and 70% case detection among infectious cases were established by the World Health Assembly in 1991. Both the WHO declaration of TB as a global emergency in 1993 and the launch of the five-element DOTS strategy in 1994-1995 resulted in countries adopting DOTS in encouraging numbers. In fact, in 2000, 148 countries including all 22 highest burden countries (HBC) responsible for 80% of cases world-wide, had adopted the new DOTS strategy. Nevertheless, progress in case detection remained slow due to incomplete geographical coverage or need to widen detection and notification capacity with innovative schemes. The major constraints to TB control became increasingly clear, and a global Stop TB Partnership was eventually established to address such constraints. A Global DOTS Expansion Plan revealed the needs and the gaps to achieve the global targets in 2005. Today, in 2002, the top priority remains that of expanding DOTS, as rapidly as possible, using a number of new approaches to increase case detection and notification while maintaining high cure rates. These must involve collaboration with the private sector and communities, as well as strengthening of primary care services. Similarly, crucial is the rapid identification of solutions to TB/HIV and MDR-TB.

Entities:  

Mesh:

Year:  2003        PMID: 12758183     DOI: 10.1016/s1472-9792(02)00071-9

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  57 in total

1.  Xer site-specific recombination, an efficient tool to introduce unmarked deletions into mycobacteria.

Authors:  Alessandro Cascioferro; Francesca Boldrin; Agnese Serafini; Roberta Provvedi; Giorgio Palù; Riccardo Manganelli
Journal:  Appl Environ Microbiol       Date:  2010-06-11       Impact factor: 4.792

2.  Immediate incubation reduces indeterminate results for QuantiFERON-TB Gold in-tube assay.

Authors:  Victor Herrera; Ellen Yeh; Kelly Murphy; Julie Parsonnet; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2010-06-02       Impact factor: 5.948

3.  The challenge of sustaining effectiveness over time: the case of the global network to stop tuberculosis.

Authors:  Kathryn Quissell; Gill Walt
Journal:  Health Policy Plan       Date:  2015-08-17       Impact factor: 3.344

4.  Access to experimental medicines for TB: ethical and human rights considerations.

Authors:  S Dagron; T Chakhaia; L González-Angulo; S Hermanns; A Skrahina; A E M Wallace
Journal:  Int J Tuberc Lung Dis       Date:  2020-05-01       Impact factor: 2.373

Review 5.  Monitoring global health: time for new solutions.

Authors:  Christopher J L Murray; Alan D Lopez; Suwit Wibulpolprasert
Journal:  BMJ       Date:  2004-11-06

6.  In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867.

Authors:  Lucio Vera-Cabrera; Jorge Castro-Garza; Adrian Rendon; Jorge Ocampo-Candiani; Oliverio Welsh; Sung Hak Choi; Kym Blackwood; Carmen Molina-Torres
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  The molecular structure of Rv1873, a conserved hypothetical protein from Mycobacterium tuberculosis, at 1.38 A resolution.

Authors:  Craig R Garen; Maia M Cherney; Ernst M Bergmann; Michael N G James
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-11-30

8.  Investigating urban-rural disparities in tuberculosis treatment outcome in England and Wales.

Authors:  I Abubakar; J P Crofts; D Gelb; A Story; N Andrews; J M Watson
Journal:  Epidemiol Infect       Date:  2007-03-15       Impact factor: 2.451

9.  Evaluation of a semi-automated reporter phage assay for susceptibility testing of Mycobacterium tuberculosis isolates in South Africa.

Authors:  Niaz Banaiee; Vanessa January; Charmaine Barthus; Maureen Lambrick; Denise Roditi; Marcel A Behr; William R Jacobs; Lafras M Steyn
Journal:  Tuberculosis (Edinb)       Date:  2007-11-05       Impact factor: 3.131

Review 10.  Revised guidelines for the diagnosis and control of tuberculosis: impact on management in the elderly.

Authors:  Paul Van den Brande
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.